Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Topchoice Medical Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Topchoice Medical wird ein jährliches Gewinn- und Umsatzwachstum von 17.2% bzw. 12.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.6% betragen.

Wichtige Informationen

17.2%

Wachstumsrate der Gewinne

17.2%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	22.1%
Wachstumsrate der Einnahmen	12.3%
Zukünftige Eigenkapitalrendite	14.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Topchoice Medical Co., Inc. (SHSE:600763) Just Reported And Analysts Are Trimming Their Forecasts

Apr 30

Recent updates

Topchoice Medical Co., Inc.'s (SHSE:600763) Intrinsic Value Is Potentially 73% Above Its Share Price

Jun 05

There's Reason For Concern Over Topchoice Medical Co., Inc.'s (SHSE:600763) Massive 27% Price Jump

May 21

Earnings Update: Topchoice Medical Co., Inc. (SHSE:600763) Just Reported And Analysts Are Trimming Their Forecasts

Apr 30

Topchoice Medical (SHSE:600763) Will Be Hoping To Turn Its Returns On Capital Around

Apr 28

Gewinn- und Umsatzwachstumsprognosen

SHSE:600763 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	4,197	794	929	1,110	8
12/31/2025	3,748	728	660	998	12
12/31/2024	3,181	579	559	914	10
3/31/2024	2,880	505	292	813	N/A
12/31/2023	2,847	500	335	840	N/A
9/30/2023	2,764	545	421	784	N/A
6/30/2023	2,763	557	243	704	N/A
3/31/2023	2,739	551	382	762	N/A
12/31/2022	2,719	548	249	670	N/A
9/30/2022	2,784	598	224	771	N/A
6/30/2022	2,781	648	394	867	N/A
3/31/2022	2,804	705	399	876	N/A
12/31/2021	2,781	703	572	939	N/A
9/30/2021	2,742	713	673	930	N/A
6/30/2021	2,652	698	721	897	N/A
3/31/2021	2,523	676	723	907	N/A
12/31/2020	2,088	493	538	708	N/A
9/30/2020	1,992	466	497	628	N/A
6/30/2020	1,838	404	389	545	N/A
3/31/2020	1,733	352	332	473	N/A
12/31/2019	1,931	466	531	659	N/A
9/30/2019	1,803	456	545	624	N/A
6/30/2019	1,708	405	517	574	N/A
3/31/2019	1,632	365	514	576	N/A
12/31/2018	1,546	332	229	469	N/A
9/30/2018	1,473	310	218	465	N/A
6/30/2018	1,357	263	163	413	N/A
3/31/2018	1,246	235	101	353	N/A
12/31/2017	1,180	217	N/A	347	N/A
9/30/2017	1,108	193	N/A	304	N/A
6/30/2017	1,006	153	N/A	241	N/A
3/31/2017	946	143	N/A	207	N/A
12/31/2016	879	136	N/A	161	N/A
9/30/2016	844	128	N/A	123	N/A
6/30/2016	801	128	N/A	141	N/A
3/31/2016	790	129	N/A	132	N/A
12/31/2015	763	124	N/A	191	N/A
9/30/2015	715	142	N/A	193	N/A
6/30/2015	670	127	N/A	152	N/A
3/31/2015	612	117	N/A	143	N/A
12/31/2014	584	110	N/A	129	N/A
9/30/2014	554	109	N/A	130	N/A
6/30/2014	518	103	N/A	123	N/A
3/31/2014	488	103	N/A	120	N/A
12/31/2013	463	100	N/A	134	N/A
9/30/2013	432	98	N/A	116	N/A
6/30/2013	409	95	N/A	114	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600763Das prognostizierte Gewinnwachstum (17.2% pro Jahr) liegt über der Sparquote (2.9%).

Ertrag vs. Markt: 600763Die Erträge des Unternehmens (17.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (23.2% pro Jahr).

Hohe Wachstumserträge: 600763Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 600763Die Einnahmen des Unternehmens (12.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (14% pro Jahr).

Hohe Wachstumseinnahmen: 600763Die Einnahmen des Unternehmens (12.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600763Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.6 %).

Topchoice Medical Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 25%

Price target decreased by 9.0% to CN¥80.80

Earnings Update: Topchoice Medical Co., Inc. (SHSE:600763) Just Reported And Analysts Are Trimming Their Forecasts

Consensus EPS estimates fall by 12%

Price target decreased by 9.3% to CN¥101

Price target decreased by 9.0% to CN¥112

Recent updates

Topchoice Medical Co., Inc.'s (SHSE:600763) Intrinsic Value Is Potentially 73% Above Its Share Price

Topchoice Medical Co., Inc., Annual General Meeting, Jun 20, 2024

There's Reason For Concern Over Topchoice Medical Co., Inc.'s (SHSE:600763) Massive 27% Price Jump

Consensus EPS estimates fall by 25%

Price target decreased by 9.0% to CN¥80.80

Earnings Update: Topchoice Medical Co., Inc. (SHSE:600763) Just Reported And Analysts Are Trimming Their Forecasts

Topchoice Medical (SHSE:600763) Will Be Hoping To Turn Its Returns On Capital Around

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Topchoice Medical Co., Inc. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 15%

Topchoice Medical Co., Inc. (SHSE:600763) completed the acquisition of 6% stake in Zhejiang Topchoice Eye Hospital Investment Management Co., Ltd. from Tong Zhihong.

Topchoice Medical Co., Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

Now 20% undervalued after recent price drop

Consensus EPS estimates fall by 12%

Price target decreased by 9.3% to CN¥101

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Topchoice Medical Co., Inc. to Report Q3, 2023 Results on Oct 25, 2023

Price target decreased by 9.0% to CN¥112

Price target decreased by 8.1% to CN¥124

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.5% to CN¥135

Less than half of directors are independent

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Topchoice Medical Corporation (SHSE:600763) announces an Equity Buyback for CNY 200 million worth of its shares.

Price target decreased to CN¥164

Second quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

Now 20% undervalued

Investor sentiment improved over the past week

Price target decreased to CN¥178

Topchoice Medical Corporation (SHSE:600763) agreed to acquire Heren Health Co., Ltd. (SZSE:300550) from Hangzhou Panyuan Investment Co., Ltd. from Hangzhou Panyuan Investment Co., Ltd. for approximately 770 million.

Consensus EPS estimates fall by 10%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥287

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Price target decreased to CN¥294

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.49 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥1.54 (vs CN¥1.44 in FY 2019)

New 90-day low: CN¥232

New 90-day high: CN¥345

New 90-day high: CN¥310

New 90-day high: CN¥284

New 90-day high: CN¥243

New 90-day high: CN¥237

Price target lowered to CN¥143

Analysts lower EPS estimates to CN¥1.58

Third-quarter earnings released: Revenue and earnings beat expectations

Third quarter earnings released

Topchoice Medical Corporation to Report Q3, 2020 Results on Oct 27, 2020

New 90-day high - CN¥199

First half earnings released

New 90-day high - CN¥176

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken